Retatrutide Dosing Guide: Schedule, Titration & What to Expect Each Week

Introduction

Retatrutide is dosed once weekly by subcutaneous injection. The Phase 3 TRIUMPH program uses a 4-week-per-step titration that starts at 2 mg and climbs to a maintenance target of 12 mg over 20 weeks. Patients who can’t tolerate the top dose can stay at 8 mg or 4 mg.

This isn’t a prescribing guide. Retatrutide isn’t FDA approved yet, so no one in the US can legally prescribe or compound it as of May 2026. But understanding the trial dosing protocol matters if you’re trying to read clinical results, prepare for future availability, or just compare retatrutide to drugs you can actually get today like semaglutide and tirzepatide.

If you want to start treatment now with an approved GLP-1 medication, TrimRx offers a free assessment quiz that matches you to compounded semaglutide or tirzepatide through licensed US pharmacies.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Retatrutide Starting Dose?

The Phase 3 TRIUMPH protocol starts patients at 2 mg subcutaneously once weekly. This is identical to the Phase 2 starting dose. The low starting dose lets the body adapt to GLP-1 and GIP receptor activation gradually, which limits early nausea and gastric upset.

Quick Answer: Phase 3 starting dose is 2 mg weekly with 4-week titration steps to 4 mg, 8 mg, then 12 mg

Two milligrams is generally below the threshold where most patients see meaningful weight loss. Average Phase 2 weight loss at 4 weeks on 2 mg was around 2 percent of body weight. The 2 mg phase is about safety and adaptation, not results.

The first injection should go in the abdomen, thigh, or upper arm. Rotation of sites week to week reduces injection site reactions. Time of day doesn’t matter pharmacologically because the 6-day half-life smooths plasma levels across the dosing interval.

How Does Retatrutide Titration Work?

The standard Phase 3 titration is:

• Weeks 1 to 4: 2 mg weekly
• Weeks 5 to 8: 4 mg weekly
• Weeks 9 to 12: 8 mg weekly
• Weeks 13 to 16: 8 mg weekly (extended hold before final step)
• Weeks 17 to 20: 12 mg weekly
• Week 20+: 12 mg maintenance

Each step lasts 4 weeks, which matches the time needed to reach steady-state plasma levels for that dose given the 6-day half-life. Going faster increases nausea and discontinuation risk. Going slower delays therapeutic benefit without meaningful safety gain.

Some Phase 2 substudies tested 2-week titration steps. Discontinuation rates climbed by 30 to 40 percent compared with 4-week steps. Lilly settled on 4 weeks as the right balance.

What Is the Maintenance Dose of Retatrutide?

The Phase 3 maintenance target is 12 mg weekly. The 8 mg dose is the fallback for patients who don’t tolerate 12 mg. Both doses produced strong weight loss in Phase 2: 22.8% at 8 mg and 24.2% at 12 mg, with the gap narrowing as the trial extended.

In practice, after FDA approval, prescribers may end up using 8 mg as a common maintenance dose because the marginal benefit over 12 mg is small while the side effect burden may be lower. The labeled doses won’t be known until the FDA approves the drug.

The 4 mg dose produced 17.1% weight loss in Phase 2, which is comparable to or better than semaglutide 2.4 mg in STEP 1 (14.9%). So 4 mg is a viable lower-tier dose for patients who want milder titration or have severe GI sensitivity.

What Should I Expect in the First Month on Retatrutide?

The first 4 weeks at 2 mg are usually quiet. Most patients in Phase 2 reported mild appetite reduction and small weight loss (2 to 4 percent) but few significant side effects. Some patients had transient nausea after the first one or two injections.

The bigger changes start at the 4 mg step. Appetite suppression deepens noticeably and food preferences shift. Many patients describe craving fewer high-fat or high-sugar foods. Weight loss accelerates to roughly 1 to 2 percent of body weight per week during the 4 mg phase for most patients.

GI side effects also peak in the first 2 weeks of each dose step. Nausea, occasional vomiting, constipation, and burping are the most common. Most resolve within 7 to 14 days of the dose change.

What Happens at the 8 Mg and 12 Mg Doses?

The 8 mg step is where Phase 2 results separated retatrutide from tirzepatide. Mean weight loss continued at roughly 0.5 to 1 percent per week at this dose without obvious plateau through week 36.

The final jump to 12 mg adds modest additional weight loss benefit (about 1.4 percentage points at week 48 over 8 mg) but increases nausea reports by about 10 to 15 percent. For most patients, 12 mg is tolerable after the prior 16 weeks of titration. For others, holding at 8 mg makes more sense.

If GI symptoms are severe at any step, the standard protocol allows stepping back down one level for 4 weeks and then retrying the higher dose. This rescue maneuver was used by about 15 percent of patients in Phase 2 and most successfully reached their target dose on the second attempt.

Key Takeaway: Half-life is about 6 days, so steady-state at each dose is reached around week 4 of that dose

How Do I Take Retatrutide Injections?

Retatrutide is supplied as a single-dose pen (similar to Wegovy® or Zepbound® pens) in the Phase 3 trials. The pen is preloaded with the dose and uses a fine 32 to 34 gauge needle. Injection technique mirrors semaglutide and tirzepatide:

1. Pull the pen from the refrigerator and let it warm for 15 to 30 minutes
2. Clean the injection site with alcohol
3. Pinch the skin gently
4. Inject perpendicular into abdomen, thigh, or upper arm
5. Hold for 5 to 10 seconds before withdrawing
6. Rotate sites weekly

If you miss a dose by less than 4 days, take it as soon as you remember. If more than 4 days, skip it and take the next dose on the regular day. Don’t double up.

Are There Special Dosing Situations to Know About?

Renal impairment: Phase 2 data showed no major pharmacokinetic differences in mild to moderate kidney disease. Severe CKD and dialysis patients haven’t been studied. The Phase 3 trial excludes severe renal impairment.

Hepatic impairment: Mild liver disease appears safe. Moderate to severe liver disease was excluded from Phase 3 enrollment.

Elderly: Patients up to 75 are included in Phase 3. Older patients may need slower titration due to higher risk of dehydration from GI side effects.

Pregnancy: Retatrutide is not approved in pregnancy. Women of reproductive age should use contraception during treatment and for at least 8 weeks (about 5 half-lives) after the last dose if planning conception.

What If I Plateau on Retatrutide?

True plateau wasn’t seen in Phase 2 at week 48 for 8 mg or 12 mg. But individual patients varied. Some lost most of their weight in the first 24 weeks and then plateaued. Others kept losing weight steadily through week 48.

If weight loss stalls for 8 weeks at any maintenance dose, options include:

• Verifying injection technique and dose
• Tightening dietary intake
• Adding resistance training (lean mass loss can stall weight progress)
• Stepping up if you’re below 12 mg

Switching to a different GLP-1 drug like tirzepatide is usually only useful if retatrutide truly fails after 6 to 12 months at maximum tolerated dose.

Does Retatrutide Need to Be Stopped Before Surgery?

The 6-day half-life means retatrutide is fully cleared from the body after about 5 weeks. The American Society of Anesthesiologists released guidance in 2023 recommending GLP-1 drugs be held for at least 7 days before procedures requiring general anesthesia due to delayed gastric emptying and aspiration risk.

For retatrutide, the practical recommendation when it becomes available will likely be holding the drug for at least one full dosing cycle (7 to 10 days) before surgery and resuming when normal eating resumes after the procedure.

Bottom line: Patients who can’t tolerate 12 mg can hold at 8 mg, which produced 22.8% weight loss at 48 weeks

FAQ

How Often Do I Inject Retatrutide?

Once weekly. Same day each week, any time of day, with or without food.

How Long Does It Take to Reach the Maintenance Dose?

20 weeks under the Phase 3 protocol if titrating all the way to 12 mg. Patients holding at 8 mg or 4 mg reach maintenance sooner.

Can I Split a Higher Dose to Make It Easier on My Stomach?

No. Retatrutide pens are single-dose. Splitting doses requires drawing from a vial, which isn’t how the Phase 3 trial supplies it. Don’t try to split doses without specific medical guidance.

What Time of Day Should I Take Retatrutide?

Any time. The 6-day half-life makes timing within the day irrelevant.

What If I Forget a Dose?

Less than 4 days late: take it as soon as you remember, then go back to your regular weekly schedule. More than 4 days late: skip it and take the next regular dose. Don’t double up.

Can I Drink Alcohol on Retatrutide?

There’s no direct drug interaction, but alcohol can worsen GI side effects in the first weeks of each dose step. Phase 2 trial data showed similar adverse events with moderate alcohol intake as with abstinence after the first month.

Is the Dosing Schedule Different for Diabetes Versus Obesity?

In Phase 3, the obesity (TRIUMPH-1, TRIUMPH-2) and diabetes (TRIUMPH-3) protocols use the same dosing schedule. Approval labels may end up with slightly different recommendations once data is reviewed.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.